智通财经5月28日电，永安药业(002365.SZ)公告称，公司股票交易于2025年5月15日至5月28日连续十个 交易日内收盘价格涨幅偏离值累计超过100%，属于股票交易严重异常波动情形。近期公司股价短期涨 幅较大，已严重偏离公司基本面，存在较高的炒作风险。公司不存在应披露未披露的重大信息。2025年 一季度，公司处于亏损状态。公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 11天7板永安药业：近期公司股价短期涨幅较大 存在较高的炒作风险 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-37 潜江永安药业股份有限公司 关于股票交易严重异常波动暨风险提示公告 （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易于 2025 年 5 月 15 日至 2025 年 5 月 28 日连续十个 交易日内收盘价格涨幅偏离值累计超过 100%，根据深圳证券交易所的有关规定， 属于股票交易严重异常波动情形。 2、近期公司股价短期涨幅较大，已严重偏离公司基本面，存在较高的炒作 风险。公司不存在应披露未披露的重大信息。2025 年一季度，公司处于亏损状 态。公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3、截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市 盈率为 106.82，滚动市盈率为 229.74，市净率为 3.34；公司所属中上协行业分 类"医药制造业"的静态市盈率为 28.22，滚动市盈率为 2 ...

Core Viewpoint - Yong'an Pharmaceutical (002365) has experienced a significant abnormal fluctuation in stock trading, with a cumulative closing price increase of over 100% from May 15 to May 28, 2025, indicating a serious deviation from the company's fundamentals and a high risk of speculation [1] Summary by Relevant Sections - Stock Trading Abnormality - The company's stock price has shown a substantial increase over a short period, leading to a classification of severe abnormal trading fluctuations [1] - Financial Performance - In the first quarter of 2025, the company reported a loss, highlighting a disconnect between stock performance and financial fundamentals [1] - Investor Advisory - The company has issued a special reminder for investors to be cautious, make rational decisions, and invest prudently due to the high speculation risk associated with the stock [1]

A股永安药业触及涨停录得11天7板，成交额12.13亿元。 订阅A股涨停捉妖队 +订阅 ...

这几只票暗盘资金正在偷偷流入，立即查看>> 永安药业（002365）触及涨停录得11天7板，成交额12.13亿元。 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要风险提示： 1、潜江永安药业股份有限公司（以下简称"公司"，证券简称：永安药业， 证券代码：002365）股票交易价格于 2025 年 5 月 23 日、2025 年 5 月 26 日、2025 年 5 月 27 日连续三个交易日内日收盘价格涨幅偏离值累计超出 20%，根据深圳 证券交易所的有关规定，属于股票交易异常波动的情况。公司股价短期涨幅较大， 敬请广大投资者理性投资，注意投资风险。 证券代码：002365 证券简称：永安药业 公告编号：2025-36 潜江永安药业股份有限公司 关于股票交易异常波动暨风险提示公告 针对公司股票交易异常波动，公司董事会对公司相关事项进行了核实，现 就有关情况说明如下： （一）经核查，公司前期披露的信息不存在需要更正、补充之处。 2、公司于 2025 年 5 月 6 日披露了《关于公司实际控制人、董事长被留置的 公告》（公告编号：2025-31），截至本公告披露日，公司暂未知悉上述事项的 进展及结论，公司将持续关注该事项后续进展情况，并根据相关规定及时履行信 息披露义务。 ...

Core Viewpoint - The pharmaceutical sector in A-shares has shown significant performance in 2025, with many stocks experiencing substantial price increases, despite a recent pullback in the market [1][2]. Group 1: Market Performance - As of May 26, the A-share market saw the Shanghai Composite Index drop by 0.05% to 3346.84 points, with the Shenzhen Component Index down 0.41% and the ChiNext Index down 0.8% [1]. - The biopharmaceutical sector has had a strong year, with five stocks rising over 100% and 35 stocks increasing by more than 50% since the beginning of 2025 [1][2]. Group 2: Individual Stock Performance - Notable performers include Yong'an Pharmaceutical, which has seen a price increase of 171.34%, and other companies like Yipin Pharmaceutical and Sanofi National Health, with increases of 169.87% and 138.47%, respectively [3][4]. - The Wind data indicates that the Wande Innovation Drug Index and the Pharmaceutical and Biological Index have risen by 11.21% and 3.17%, respectively, outperforming major indices like the Shanghai Composite and CSI 300 [2]. Group 3: Factors Driving Stock Prices - Yong'an Pharmaceutical's stock price surge is attributed to rising international prices of taurine and strong sales performance of its functional beverage brand "Yijianeng" on e-commerce platforms [5]. - The recent authorization deal between Sanofi Pharmaceutical and Pfizer for a breakthrough PD-1/VEGF bispecific antibody has also driven stock prices, with potential total transaction value exceeding $6 billion [9]. - The acceleration of innovative drug development and the increasing focus on AI in healthcare are contributing factors to the rising stock prices of several pharmaceutical companies [10]. Group 4: Future Outlook - Analysts are optimistic about the investment opportunities in innovative drugs for the second half of 2025, citing the international competitiveness of China's innovative drug development [12]. - The pharmaceutical industry is expected to benefit from ongoing innovation, demographic trends, and favorable policy environments, with a focus on innovative drugs and consumer recovery [12].

Market Performance - On May 23, major market indices experienced fluctuations and closed lower, with A-shares trading volume reaching 1.18 trillion yuan, and over 1,100 stocks closing higher, including 52 stocks hitting the daily limit [1] - For the week, the Shanghai Composite Index fell by 0.57%, the ChiNext Index dropped by 0.88%, and the STAR Market 50 Index decreased by 1.47% [1] Individual Stock Performance - Over 1,600 stocks rose this week, with 22 stocks gaining over 30%. Notably, six stocks surged over 50%, with the largest increase being 99.96% for Sanofi [1][2] - Other significant gainers included Huibo Yuntong (301316) and Binhai Energy (000695), both of which saw weekly increases exceeding 60% [1][2] Sector Analysis - Among the stocks that rose over 30%, the pharmaceutical and biological sector had six representatives, followed by light industry manufacturing with three stocks [1] Historical Highs - On May 23, 17 stocks reached historical closing highs, with the pharmaceutical and biological, mechanical equipment, and automotive sectors showing a concentration of high performers [3][4] - The average increase for stocks reaching historical highs was 8.20%, with notable gainers including Xintiandi (301277) and Zhongzhou Special Materials (300963) [3] Institutional Activity - On May 23, ten stocks saw net purchases from institutions, with Yixin Tang (002727) leading at a net buy of 102 million yuan [5][6] - Conversely, institutions sold off stocks such as Hongchuang Holdings (002379) and Tianqimo (002510), each experiencing net sales exceeding 50 million yuan [5][6] Northbound Capital Flow - Northbound capital was present in nine stocks on the trading board, with net purchases in three stocks: Xue Ren Shares (002639), Huibo Yuntong, and Jinlongyu (002882) [7] - Yixin Tang faced the highest net sell-off from northbound capital, totaling 68.98 million yuan [7] Company Announcements - Zhongjin Gold (600489) plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [8] - Huakang Clean (301235) won a bid for a healthcare project with a contract value of 60.24 million yuan and a duration of 120 days [8] - Weier Shares (603501) intends to issue H-shares and list on the Hong Kong Stock Exchange [9] - Yunchongma (603130) plans to raise no more than 640 million yuan for a project to produce DTY silk and high-performance leather base fabric [9]

近半年该股累计上榜龙虎榜15次，上榜次日股价平均涨3.92%，上榜后5日平均涨8.63%。 资金流向方面，今日该股主力资金净流出1705.61万元，其中，特大单净流入3611.90万元，大单资金净 流出5317.51万元。近5日主力资金净流入3.26亿元。（数据宝） 永安药业今日涨停，全天换手率34.93%，成交额17.16亿元，振幅6.04%。龙虎榜数据显示，机构净买入 1877.17万元，营业部席位合计净卖出308.37万元。 深交所公开信息显示，当日该股因日涨幅偏离值达10.89%、日换手率达34.93%上榜，机构专用席位净 买入1877.17万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交3.69亿元，其中，买入成交额为1.92亿 元，卖出成交额为1.77亿元，合计净买入1568.80万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即买二、买三、卖二、卖三、卖五，合 计买入金额7286.16万元，卖出金额5408.99万元，合计净买入1877.17万元。 永安药业5月23日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | ...

Core Viewpoint - The surge in taurine prices and the popularity of functional beverages have significantly driven the stock price of Yong'an Pharmaceutical, which has seen a remarkable increase in recent weeks [2][9]. Group 1: Taurine Market Dynamics - Yong'an Pharmaceutical, the largest taurine producer globally, is projected to achieve approximately 635 million yuan in revenue from taurine raw materials in 2024, accounting for 75.69% of total revenue [7]. - Recent international taurine prices have exceeded $10 per kilogram, driven by trade war price expectations and U.S. regulations mandating taurine in infant formula and pet food [7][8]. - The global demand for taurine is estimated at 160,000 tons annually, while current production capacity is only 140,000 tons, resulting in a shortfall of about 20,000 tons [8]. Group 2: Functional Beverage Market Entry - Yong'an Pharmaceutical has successfully entered the functional beverage market, contributing to its recent stock price surge [9]. - The company's solid functional beverage brand, Yijianeng, has achieved significant sales, ranking first in popularity on various e-commerce platforms [10]. - The functional beverage market in China is projected to grow to 166.5 billion yuan by 2024, with a compound annual growth rate of 8.3% from 2019 to 2024, indicating substantial growth potential [10][11]. Group 3: Strategic Initiatives - The company has focused on the anti-fatigue market for its functional beverage offerings, with plans to launch its self-branded products by the end of 2024 [11]. - Yong'an Pharmaceutical is actively involved in the research, development, and production of taurine-based functional foods and health products [11].